# Collegium Pharmaceutical Inc. (COLL)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.36B  
**Price:** $34.34 (-1.32%)

> Collegium Pharmaceutical is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and neuropsychiatric conditions. The company's primary portfolio includes Jornay PM, a central nervous system stimulant for attention deficit hyperactivity disorder; Belbuca, a buccal film containing buprenorphine for chronic pain; and Xtampza ER, an abuse-deterrent extended-release oral formulation of oxycodone. Collegium also offers Nucynta products in extended-release and immediate-release formulations, along with Symproic for opioid-induced constipation. The company employs proprietary DETERx platform technology designed to maintain safety profiles while deterring abuse through various manipulation methods. Headquartered in Stoughton, Massachusetts, and founded in 2002, Collegium serves healthcare providers and patients across the United States, positioning itself as a leader in responsible pain management and ADHD treatment.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $781M | $463M | $180M | $63M | — |
| 2024 | $631M | $377M | $170M | $69M | — |
| 2023 | $567M | $326M | $167M | $48M | — |
| 2022 | $464M | $209M | $33M | -$25M | — |
| 2021 | $277M | $151M | $18M | $72M | — |
| 2020 | $310M | $180M | $56M | $27M | — |
| 2019 | $297M | $103M | -$24M | -$23M | — |
| 2018 | $280M | $115M | -$21M | -$39M | — |
| 2017 | $28M | $26M | -$75M | -$75M | — |
| 2016 | $2M | $1M | -$94M | -$94M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.66B | $1.36B | $302M | $231M | — |
| 2024 | $1.66B | $1.43B | $229M | $71M | — |
| 2023 | $1.14B | $948M | $195M | $239M | — |
| 2022 | $1.17B | $979M | $195M | $174M | — |
| 2021 | $692M | $489M | $203M | $186M | — |
| 2020 | $644M | $458M | $186M | $174M | — |
| 2019 | $306M | $219M | $87M | $170M | $12M |
| 2018 | $291M | $200M | $92M | $147M | $12M |
| 2017 | $136M | $31M | $104M | $119M | — |
| 2016 | $162M | $27M | $135M | $153M | $4M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $329M | $2M | $328M |
| 2024 | $205M | $2M | $203M |
| 2023 | $275M | $461,000 | $274M |
| 2022 | $124M | $2M | $123M |
| 2021 | $104M | $2M | $102M |
| 2020 | $94M | $6M | $88M |
| 2019 | $28M | $6M | $21M |
| 2018 | $169M | $5M | $164M |
| 2017 | -$67M | $990,000 | -$68M |
| 2016 | -$75M | $477,000 | -$76M |
| 2015 | -$22M | $362,000 | -$22M |

Source: [CompaniesByCap](https://companiesbycap.com/company/COLL)